Patient characteristics (allergic donors)
| Patient no. . | Age, y . | f/m . | Symptoms . | Therapy . | Allergen-specific IgE – CLA/RAST class . | SPT . | ||
|---|---|---|---|---|---|---|---|---|
| HDM . | BP . | TGP . | ||||||
| 1 | 26 | m | RC, U | AH* | 4(c)/3(r) | 4(c)/5(r) | 4(c)/4(r) | nt |
| 2 | 28 | m | RC | AH* | 1(c)/nt | 1(c)/nt | 4(c)/4(r) | + |
| 3 | 27 | f | RC, D | AH* | nt/nt | 4(c)/nt | 4(c)/nt | + |
| 4 | 24 | m | RC, D | AH* | 3(c)/nt | 4(c)/nt | 4(c)/nt | nt |
| 5 | 45 | m | RC | No | nt/nt | 4(c)/nt | nt/nt | nt |
| 6 | 26 | m | RC | AH* | 4(c)/nt | 4(c)/nt | 4(c)/nt | nt |
| 7 | 27 | f | RC | AH* | nt/6(r) | nt/6(c) | nt/6(r) | nt |
| 8 | 34 | f | RC | AH* | nt/nt | nt/nt | nt/3(r) | + |
| 9 | 25 | m | RC, D, P | AH*, CS* | 1(c)/nt | 4(c)/nt | 4(c)/nt | nt |
| 10 | 62 | m | RC, AA, U | CS | nt/3(r) | nt/4(r) | nt/3(r) | + |
| 11 | 24 | f | RC | No | 4(c)/nt | nt/nt | 1(c)/nt | nt |
| 12 | 27 | m | RC | No | 4(c)/nt | nt/nt | nt/nt | + |
| 13 | 22 | f | RC | No | nt/3(r) | nt/3(r) | nt/nt | + |
| 14 | 23 | f | RC, D | AH* | nt/4(r) | nt/6(r) | nt/nt | + |
| 15 | 17 | f | RC, D | CS | 4(c)/nt | nt/nt | nt/nt | + |
| 16 | 24 | f | RC | No | 4(c)/nt | nt/nt | nt/nt | nt |
| 17 | 30 | f | RC, D | AH* | 4(c)/nt | 2(c)/nt | 4(c)/nt | + |
| 18 | 32 | m | RC, AA | CS | 4(c)/nt | 4(c)/nt | 4(c)/nt | + |
| Patient no. . | Age, y . | f/m . | Symptoms . | Therapy . | Allergen-specific IgE – CLA/RAST class . | SPT . | ||
|---|---|---|---|---|---|---|---|---|
| HDM . | BP . | TGP . | ||||||
| 1 | 26 | m | RC, U | AH* | 4(c)/3(r) | 4(c)/5(r) | 4(c)/4(r) | nt |
| 2 | 28 | m | RC | AH* | 1(c)/nt | 1(c)/nt | 4(c)/4(r) | + |
| 3 | 27 | f | RC, D | AH* | nt/nt | 4(c)/nt | 4(c)/nt | + |
| 4 | 24 | m | RC, D | AH* | 3(c)/nt | 4(c)/nt | 4(c)/nt | nt |
| 5 | 45 | m | RC | No | nt/nt | 4(c)/nt | nt/nt | nt |
| 6 | 26 | m | RC | AH* | 4(c)/nt | 4(c)/nt | 4(c)/nt | nt |
| 7 | 27 | f | RC | AH* | nt/6(r) | nt/6(c) | nt/6(r) | nt |
| 8 | 34 | f | RC | AH* | nt/nt | nt/nt | nt/3(r) | + |
| 9 | 25 | m | RC, D, P | AH*, CS* | 1(c)/nt | 4(c)/nt | 4(c)/nt | nt |
| 10 | 62 | m | RC, AA, U | CS | nt/3(r) | nt/4(r) | nt/3(r) | + |
| 11 | 24 | f | RC | No | 4(c)/nt | nt/nt | 1(c)/nt | nt |
| 12 | 27 | m | RC | No | 4(c)/nt | nt/nt | nt/nt | + |
| 13 | 22 | f | RC | No | nt/3(r) | nt/3(r) | nt/nt | + |
| 14 | 23 | f | RC, D | AH* | nt/4(r) | nt/6(r) | nt/nt | + |
| 15 | 17 | f | RC, D | CS | 4(c)/nt | nt/nt | nt/nt | + |
| 16 | 24 | f | RC | No | 4(c)/nt | nt/nt | nt/nt | nt |
| 17 | 30 | f | RC, D | AH* | 4(c)/nt | 2(c)/nt | 4(c)/nt | + |
| 18 | 32 | m | RC, AA | CS | 4(c)/nt | 4(c)/nt | 4(c)/nt | + |
The CLA class was defined by the following score: 0, 0-26 luminescence units (LU); 1, 27-65 LU; 2, 66-142 LU; 3, 143-242 LU; and 4, more than 242 LU. The RAST class was defined by the following score: 0, 0-0.34 kUA/L; 1, 0.35-0.69 kUA/L; 2, 0.70-3.49 kUA/L; 3, 3.50-17.49 kUA/L; 4, 17.50-49.99 kUA/L; 5, 50.00-99.99 kUA/L; and 6, 100 kUA/L or more.
f indicates female; m, male; CLA, chemiluminescence (c); RAST, radioallergosorbent test (r); SPT, skin prick test; HDM, house dust mite; BP, birch pollen; TGP, timothy grass pollen; RC, rhinoconjunctivitis; U, urticaria; AH, antihistamines; nt, not tested; D, dyspnea; P, pruritus; CS, corticosteroids; and AA, allergic asthma.
These drugs were taken only on demand by patients.